The four top legal department leaders overseeing a new $26 billion opioid settlement are longtime veterans of their companies, with their tenure stretching back to some of the underlying corporate conduct at issue and in the early days of settlement negotiations. And the four likely had a heavy hand in crafting the final proposal.

The proposed settlement, which would end about 4,000 lawsuits across the country over the opioid epidemic, entails payments over the course of 18 years, including drug distributors AmerisourceBergen paying $6.4 billion, Cardinal Health paying $6.4 billion and McKesson paying $7.9 billion. Drug manufacturer Johnson & Johnson would pay $5 billion over the course of nine years.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]